

AMENDMENTS

In the claims:

1. (Original) A pharmaceutical composition, comprising a solubilizing agent selected from crystalline methylated α -, β -, and γ -cyclodextrin, or mixtures thereof, and a pharmaceutically active agent.
2. (Original) The composition of claim 1, wherein the solubilizing agent is crystalline methylated β -cyclodextrin.
3. (Original) The composition of claim 1, wherein the active agent is one that has poor aqueous solubility.
4. (Original) The composition of claim 1, which is an oral or parenteral solution.
5. (Original) The composition of claim 1, which is a liquid or cream preparation for external use.
6. (Original) The composition of claim 1, which is in the form of a solid dosage unit.
7. (Original) The composition of claim 1, which is a solid oral dosage unit.
8. (Original) The composition of claim 1, which is a tablet or capsule.
9. (Original) The composition of claim 1, which is an osmotic dosage unit.
10. (Original) The composition of claim 1, wherein the active agent is carbamazepine, fenofibrate, oxcarbazepine, or glipizide.